Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting

NCT07378839 | Recruiting

• 1 other identifier: OBGYN-2025-34216
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This is a prospective, two-arm, non-blinded randomized controlled study designed to evaluate the effects of a one-week alternate nostril breathing (ANB) intervention on nausea and vomiting severity in pregnant individuals during their first trimester.

Conditions

Pregnancy Emesis; Nausea

Outcome Measures

Primary Outcomes (1)

• Severity of Nausea and Vomiting

  Measured by the change in the Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) score, where scores range from 3-15, and a higher score indicates greater severity of nausea and vomiting.

  Day 7

Study Arms (2)

Alternate Nostril Breathing

ACTIVE COMPARATOR

Participants in the intervention group will receive a brief orientation via a research team member at the time of randomization on alternate nostril breathing (ANB) and then be provided with a written and video-based instructional guide. They will be instructed to perform ANB 3 times per day for 5-10 minutes per session over a 7-day period and document their sessions in a daily symptom diary. The 7-day period will begin the following day after enrollment to allow for a full day of intervention implementation (Day 1-7).

Behavioral: Alternate Nostril Breathing

Usual Care Only

NO INTERVENTION

This group will receive usual care and complete a daily symptom diary for Day 1-7.

Interventions

Alternate Nostril Breathing BEHAVIORAL

ANB 3 times per day for 5-10 minutes per session over a 7-day period

Alternate Nostril Breathing

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Pregnant individuals aged 18 years or older
• Viable pregnancy with a gestational age between 6 0/7 - 12 6/7 weeks of gestation, confirmed by last menstrual period or ultrasound
• Diagnosed with mild to moderate NVP (PUQE-24 score between 4-12)
• Ability to understand and read English

You may not qualify if:

• Severe nausea and vomiting, defined as a PUQE score \>12, or diagnosis of hyperemesis gravidarum requiring hospitalization or intravenous fluid therapy
• Pre-existing, active or acute respiratory conditions (e.g., asthma, COPD)
• History of severe anxiety disorders affecting breathing patterns
• Known deviated nasal septum
• Nausea and vomiting that pre-dates the pregnancy or is suspected to be due to a etiology other than pregnancy

Sponsors & Collaborators

• University of Minnesota: lead

Study Sites (1)

University of Minnesota

Minneapolis, Minnesota, 55455, United States

RECRUITING

MeSH Terms

Conditions

Nausea

Condition Hierarchy (Ancestors)

Signs and Symptoms, Digestive; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Shilpa Babbar

  University of Minnesota

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Erin Wesley

CONTACT

612-624-9208; obgynresearch@umn.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 23, 2026
• First Posted: January 30, 2026
• Study Start: February 10, 2026
• Primary Completion (Estimated): March 31, 2027
• Study Completion (Estimated): March 31, 2027
• Last Updated: March 19, 2026

Record last verified: 2026-03

Locations

US (1)